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Monitoring HIV drug resistance is an important component of the World Health Organization’s global HIV
program. HIV drug resistance testing is optimal with commercially available clinically validated test kits using
plasma; however, that type of testing may not be feasible or affordable in resource-constrained settings. HIV
genotyping from dried blood spots (DBS) with noncommercial (in-house) assays may facilitate the capture of
HIV drug resistance outcomes in resource-constrained settings but has had varying rates of success. With
in-house assays for HIV reverse transcriptase, we evaluated the yield of genotyping DBS samples collected from
HIV-infected children who were enrolled in two clinical trials conducted in sub-Saharan Africa (median HIV
viral load, 5.88 log10 HIV RNA copies/ml; range, 4.04 to 6.99). Overall, HIV genotypes were obtained for 94
(89.5%) of 105 samples tested (95% and 84% from clinical trials #1 and #2, respectively); however, successful
analysis of 15 (16.1%) of the 94 samples required repeat testing using a different set of primers on previously
synthesized cDNA. The yield of genotyping was lower on the DBS that were stored suboptimally from clinical
trial #2 (56% versus 88% for optimally stored). Concordance with plasma genotypes derived using a clinically
validated, commercial kit-based assay (ViroSeq HIV-1 genotyping system) was also assessed in a subset of
children with paired testing. For 34 samples with paired DBS and plasma genotypes, there was 100% concordance for major drug resistance mutations. DBS genotyping using in-house assays provides an alternative for
antiretroviral drug resistance testing in children in resource-constrained regions but may require regionspecific optimization before widespread use.
ing of HIV drug resistance in infected persons residing in
resource-constrained settings (2–5, 7–9).
The use of in-house assays that amplify HIV reverse transcriptase (HIV-RT) and protease separately and include a
nested PCR step may improve the sensitivity of genotyping
DBS over that obtained with commercially available assays
which amplify HIV-RT and protease in a single amplicon
(⬎1,500 bp) with a single round of PCR (2, 4). The success
levels of HIV genotyping of DBS with in-house and commercial assays (Trugene or ViroSeq) are reported as between 90
and 100% and between 57% to 83%, respectively (2). We
previously reported a success rate of 94% of genotyping DBS
from subtype B HIV-infected youths with an in-house assay. A
high concordance between results obtained with this in-house
assay was found between DBS and plasma samples. In that
study, the 12 samples tested had a median viral load of 17,792
copies/ml (range of ⬍50 to 105,000 copies/ml) (17). In this
study, the success of genotyping pretreatment samples collected as DBS from children infected with non-subtype-B HIV
who were likely to have HIV drug resistance due to exposure to
nevirapine (NVP) for prevention of mother-to-child HIV transmission was examined. We report on the necessity for additional

With the scale-up of programs for using antiretroviral drugs
to prevent and treat HIV infection in children globally, the
prevalence of HIV drug resistance is likely to increase. Surveillance of HIV drug resistance is an important component of
the World Health Organization (WHO) global drug resistance
and prevention strategy (2, 15). The availability of HIV drug
resistance testing is limited in resource-constrained settings
due to the high cost of such assays as well as their need for
plasma samples, which requires processing of whole blood
within hours of collection to minimize the degradation of viral
nucleic acid. The use of clinically validated, kit-based genotyping assays that are commercially available may further limit
HIV drug resistance testing in such settings due to cost and the
possible lack of a steady supply of test reagents. Use of dried
blood spots (DBS) rather than plasma samples and of in-house
assays rather than commercial test kits may facilitate monitor* Corresponding author. Mailing address: Johns Hopkins University
School of Medicine, 720 Rutland Avenue, Ross Building Room 1170,
Baltimore, MD 21205. Phone: (443) 287-3733. Fax: (410) 614-1315.
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TABLE 1. Primers and conditions used for HIV genotyping from DBSa

Assay type

Assay #1b

Assay #2c

Step

Primer sequence (5⬘–3⬘)

Product
size (bp)

HXB2
position

Incubation conditions

50°C ⫻ 50 min, 85°C ⫻
5 min
94°C ⫻ 3 min; 32 cycles
of 94°C ⫻ 30 s, 55°C
⫻ 30 s, 68°C ⫻ 45 s;
68°C ⫻ 5 min

RT

3outRTb

GGCTGTACTGTCCATTTA

NA

3277–3260

1st round PCR

5outRTb (F)
3outRTb (R)

GTCCTRTTGAAACTGTAC
GGCTGTACTGTCCATTTA

720

2557–3277

2nd round PCR

5innRTb (F)
3innRTb (R)

ATGGCCCAAAAGTYAAAC
TTATCAGGATGGAGTTCA

663

2599–3262

94°C ⫻ 3 min; 32 cycles
of 94°C ⫻ 30 s, 52°C
⫻ 30 s, 68°C ⫻ 45 s;
68°C ⫻ 5 min

RT
Amplicon 2

cDNA template the same as for initial assaye
2F-HIVC (F) GCCTCCCTCGCGCCATCAGGGAAGTTC
AATTAGGRATACCACACCC
2R-HVC (R) GCCTTGCCAGCCCGCTCAGAGGGCTCT
AAGATTYTTGTCAT
3F-HIVC (F) GCCTCCCTCGCGCCATCAGAGAGCCCT
TTAGAGCAMAAAAYCCAGA
3R-HIVC (R) GCCTTGCCAGCCCGCTCAGCTGTATAG
GCTGTACTGTCCATTTGTC
4F-HIVC (F) GCCTCCCTCGCGCCATCAGGTACCAGT
AAAATTAAAGCCAGGAATGG
4R-HIVC (R) GCCTTGCCAGCCCGCTCAGATACTAGG
TATGGTGAATGCAGTATAYTT
5F-HIVC (F) GCCTCCCTCGCGCCATCAGCACCAGGG
ATTAGATATCARTAYAATGT
5R-HIVC (R) GCCTTGCCAGCCCGCTCAGAACTTCTG
TATATCATTGACAGTCCA

247

2813–3060

94°C ⫻ 3 min; 40 cycles
of 94°C ⫻ 15 s, 55°C
⫻ 20 s, 72°C ⫻ 30 s;
72°C ⫻ 8 min

227

3057–3284

382

2571–2953

363

2965–3328

Amplicon 3

Amplicon 4

Amplicon 5

Assay #3d

Primer name

RT

5Rcdna

AACTTCTGTATATCATTGACAGTCCA

NA

3328–3303

1st round PCR

4F-HIVC (F)
5R-HIVC (R)

GCCTCCCTCGCGCCATCAGGTACCAGT
AAAATTAAAGCCAGGAATGG
GCCTTGCCAGCCCGCTCAGAACTTCTG
TATATCATTGACAGTCCA

757

2571–3328

2nd round PCR

Same as assay #1

42°C ⫻ 50 min, 70°C ⫻
15 min
94°C ⫻ 3 min; 40 cycles
of 94°C ⫻ 30 s, 55°C
⫻ 30 s, 72°C ⫻ 90 s;
72°C ⫻ 8 min

a

Primers used in amplification were also used as the sequencing primers. NA, not applicable; F, forward; R, reverse.
Previously published method (17).
c
Multiple short amplicons were amplified using 25-l reaction mixtures containing the four different primer pairs at a final concentration of 0.4 M and 2.5 U of
FastStart high-fidelity enzyme blend (Roche Applied Science, Mannheim, Germany) (13). Assay #2 was used to repeat genotyping for samples that failed to amplify
using assay #1 or assay #3.
d
The first-round of PCR for assay #3 in a 50-l reaction mixture containing the amplicon 4 forward primer, 4F-HIVC, and amplicon 5 reverse primer, 5R-HIVC,
at a final concentration of 0.4 M and 2.5 U of FastStart high-fidelity enzyme blend (Roche Applied Science, Mannheim, Germany).
e
Assay #2 used the same cDNA template that was used in the first assay.
b

testing with different primers to improve the overall yield of genotyping DBS samples from different geographic regions.
MATERIALS AND METHODS
Study population. DBS samples were collected from HIV-infected infants and
children enrolled in two clinical trials: (i) the Six Week Extended Nevirapine
Trial (SWEN trial; ClinicalTrials.gov number NCT00074399) (1, 12), and (ii) the
P1060 trial (ClinicalTrials.gov number NCT00307151) (11). The SWEN trial,
conducted in Uganda, India, and Ethiopia, compared the effectiveness of singledose nevirapine (sdNVP) to that of up to 6 weeks of extended daily infant
nevirapine (NVP) prophylaxis for the prevention of postnatal HIV transmission
(1). The P1060 trial, conducted in South Africa, Malawi, Tanzania, India, Zambia, Uganda, and Zimbabwe, compared the efficacy of a NVP-based regimen to
that of a protease inhibitor-based regimen for the treatment of HIV-infected
children who did or did not receive sdNVP prophylaxis at birth (11). The
following sets of DBS samples were analyzed: (i) for the SWEN trial, 58 DBS
samples collected from Ethiopian infants at 6 months of age, and (ii) for the

P1060 trial, 49 DBS samples collected from sdNVP-exposed children aged 6 to
22 months. DBS samples tested in this study were collected prior to the initiation
of antiretroviral drugs for the treatment of HIV infection.
Collection and storage of DBS samples. In both clinical trials, EDTA-anticoagulated whole blood (50 l) was spotted and air dried onto each of five circles
of filter paper (Whatman No. 903; Florham Park, NJ). DBS cards were stored
according to instructions defined by the clinical trial. For the SWEN trial, DBS
were stored at study sites for 1 to 6 years at ⫺20°C to ⫺40°C; DBS cards from
the P1060 trial were stored for 0.3 to 1.8 years at ⫺20°C to ⫺40°C. DBS cards
from both sites were shipped to the Johns Hopkins University (JHU) at ambient
temperature. DBS were stored in their original packing until processing at 4°C
(SWEN samples) and ⫺20°C (P1060 samples). Some of the DBS cards from the
P1060 trial were assessed at the time of processing as suboptimal since they were
not in air-impermeable bags with silica desiccant as recommended in the guidelines by the WHO (16).
Viral load testing. In the SWEN trial, HIV viral load tests were performed in
a CLIA-certified laboratory at JHU using a single spot from a DBS card (Roche
Amplicor HIV-1 monitor test, version 1.5; Roche Diagnostics, Branchburg, NJ).
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FIG. 1. Amplicons produced using in-house HIV genotyping assays
(see text). The positions of amplicons in HIV genotyping assays described in Table 1 are shown. Solid lines show the first-round PCR
amplicons, and dotted lines show the amplicons produced in nested
PCR. Three assays were used for analysis (#1, #2, and #3). Assay #2
produces four short, overlapping amplicons (#2-2, #2-3, #2-4, and
#2-5). PRO, HIV protease; RT, HIV reverse transcriptase. Numbers
above the diagram indicate coordinates in HXB2.

Spots from the same DBS card were used for HIV genotyping. In the P1060 trial,
HIV viral load tests were performed using plasma samples collected at the same
time as the samples that were used to prepare DBS. In the P1060 trial, viral loads
were determined in different laboratories using one of several commercially
available test kits, as previously described (11).
Extraction of nucleic acid from DBS. Spots were punched from DBS cards
using a 0.5-in. (1.2-cm) custom-made hole puncher (Online River, LLC, Greenwich, CT) and were deposited into a tube containing 9 ml of lysis buffer (bioMérieux, Durham, NC). In the SWEN trial, the two spots (prepared with a total
of 100 l of blood) were used for genotyping as recommended by the WHO (16).
In the P1060 trial, however, five spots were used based on one of the study
objectives to assess the emergence of HIV drug resistance at 4 weeks during
antiretroviral therapy, when plasma HIV RNA is expected to be significantly
lower than pretreatment levels. Five spots of whole blood are nearly equivalent
to 100 l of plasma. Nucleic acid (RNA and DNA) was extracted from the first
10 samples in the SWEN trial by using a manual NucliSENS silica-based extraction method; the rest of the samples were processed using a semiautomated
NucliSENS silica-based extraction method (bioMérieux, Durham, NC). Two
DBS samples from the SWEN trial were excluded from analysis because of
technical problems that arose during the manual nucleic acid extraction step.
Since the rest of the spots were consumed for infant diagnosis and viral load
testing, no additional spots were available for testing, and the remaining 56
samples from this trial were analyzed. For extraction (both manual and automated), the tubes were rocked at room temperature for 1 h. Nucleic acid was
then isolated using silica beads according to the manufacturer’s instructions and
was eluted using 60 l of elution buffer in a tube containing 40 U of RNAseOUT
(Invitrogen, Carlsbad, CA).
HIV genotyping. The success rates of genotyping from DBS were compared
using three different genotyping methods (referred to here as assay #1, assay #2,
and assay #3) (Table 1; Fig. 1). Given the lower-than-expected frequency of
amplification of non-subtype-B samples from the SWEN trial using our previously published assay (assay #1) (Table 1) (17), we used a second approach
(assay #2) that included even smaller overlapping HIV amplicons (227 to 382
bp) (10, 13); that approach had been used successfully to genotype non-sub-
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type-B plasma samples using ultradeep pyrosequencing from children in a previous study (10, 13). A third assay was subsequently developed that used a
combination of primers from assay #2 for the first round of PCR and the nested
PCR primers and conditions for assay #1. HIV RNA was first reverse transcribed to produce cDNA (Table 1). An aliquot of the cDNA was then amplified
using one of the three methods described in Table 1. In the SWEN trial, for
samples that were not successfully amplified using assay #1, the cDNA was
reamplified using assay #2 (10, 13). Given the improved performance of genotyping DBS when assay #2 was used to retest samples that were not amplified
using assay #1, a new PCR amplification assay (assay #3) was developed and
used for the second clinical trial (P1060) as the first test method. The cDNA was
reamplified using assay #2 if negative, as was done for samples from the SWEN
trial.
Amplified DNA was analyzed by agarose gel electrophoresis, purified using
the QIAquick PCR purification kit (Qiagen, Valencia, CA), and sequenced using
an ABI 3730 capillary electrophoresis instrument (Applied Biosystems, South
San Francisco, CA) with HIV reverse transcriptase-specific sequencing primers
(Table 1), as previously described (17).
Plasma samples from the P1060 trial were also analyzed in a previous study
using the ViroSeq HIV-1 genotyping system (Celera, Alameda CA) (11). The
ViroSeq system detects mutations in HIV protease and HIV reverse transcriptase; the methods used for DBS analysis in this report provide information only
about mutations in HIV reverse transcriptase. Testing using plasma and DBS
were performed by different personnel in different laboratories. Resistance test
results were not compared until all of the testing was completed.
Analysis of HIV drug resistance mutations. HIV sequences derived from DBS
genotyping were aligned to subtype C HIV reference sequences from the Los
Alamos database (http://www.HIV.lanl.gov/content/index/) using Sequencher
4.9 software (GeneCodes, Ann Arbor, MI). Polymorphisms were visualized in
BioEdit 7.0.9 (Ibis Bioscience, Carlsbad, CA). HIV subtypes were assessed using
neighbor-joining phylogenetic trees synthesized in Mega 4.0 (http://www
.megasoftware.net/). These methods were also used to compare the sequences
from DBS samples and to compare sequences from DBS and plasma samples.
Nonnucleoside reverse transcriptase inhibitor (NNRTI) and nucleoside reverse
transcriptase inhibitor (nRTI) drug resistance mutations were interpreted using
the Stanford Drug Resistance Database (http://HIVdb.stanford.edu/).
Statistical analysis. Statistical analysis was performed using Stata version 11.
Fisher’s exact tests were used to compare differences in performance of genotyping using the various assays.

RESULTS
HIV genotyping of DBS samples. Table 2 shows the source
of the DBS samples used for analysis, the duration of sample
storage at the study sites, the viral loads of the samples, and the
results of HIV genotyping. Amplification was successful for 41
(73%) of 56 of the samples from the SWEN trial using assay
#1 only. A second amplification using assay #2 on previously
synthesized cDNA was successful for 12 of the 15 samples that
did not amplify with assay #1. Using this combined approach
(assay #1 followed by assay #2), 53 (95%) of the 56 samples
from the SWEN trial were successfully genotyped with complete coverage of known sites of drug resistance in up to amino

TABLE 2. Yield of HIV genotyping of DBS samples collected in clinical trials in sub-Saharan Africa
Clinical
trial

SWEN
P1060

a

Median duration (yr)
of sample storageb

No. of
samplesc

Median log10
HIV viral
load (range)

Assay #1

Assay #3

All
All
Optimal storage
Suboptimal storage

3.3
1
0.5
1.2

56
49
33
16

5.9 (4.0–7.0)
5.8 (4.6–6.9)
6.0 (4.6–6.9)
5.9 (5.5–6.4)

41/56 (73%)
NA
NA
NA

NA
38/49 (78%)
29/33 (88%)
9/16 (56%)

NA, not applicable.
Duration of storage at study sites prior to sample shipment.
Samples and sample storage are described in Materials and Methods.
d
Assay #2 was performed if assay #1 or #3 failed to yield genotype (see Materials and Methods).
b
c

Yield (%) of HIV
genotyping usinga:

Sample subset

Overall recovery (%)
with retestingd

53/56 (95%)
41/49 (84%)
30/33 (91%)
11/16 (69%)
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FIG. 2. Phylogenetic relationships of sequences obtained from matched dried-blood-spot and plasma samples (P1060 trial). A phylogenetic tree
constructed using sequences obtained using DBS samples (n ⫽ 41; 41 symbols) or plasma samples (n ⫽ 34; 34 symbols) is shown; 34 of the samples
are matched (prepared from the same whole-blood collection). Reference sequences for subtype C are indicated with “C.” Mutations detected in
the samples are shown.

acid 260 in HIV reverse transcriptase. The three samples that
were retested were considered to be amplification failures,
even though PCR products were detected by gel electrophoresis, because only partial coverage of HIV reverse transcriptase was obtained.
Based on these results, assay #3 was used to first test samples from the second clinical trial. Using assay #3, 38 (78%) of
49 samples from the P1060 trial were successfully genotyped.
Because some of the samples from the P1060 trial were not
properly stored (see Materials and Methods), we compared
the genotyping success rates for samples that were compared
with those that were not properly stored (Table 2). The proportion of samples successfully genotyped using assay #3 was
higher for samples that were stored properly than for samples
that were not stored properly (29/33 ⫽ 88% versus 9/16 ⫽
56%; P ⫽ 0.03) (Table 2). The 11 samples from the P1060 trial
that failed to amplify with assay #3 were retested using assay
#2 as was done for samples from the first clinical trial; 3 (27%)
of those 11 samples were successfully amplified. Using this
combined approach (assay #3 followed by assay #2), we were
able to genotype 30 (91%) of the 33 samples that were stored

properly and 11 (69%) of the 16 samples that were not stored
properly (overall success rate, 41/49 ⫽ 84%) (Table 2).
Detection of drug resistance in DBS samples. As expected,
NNRTI resistance mutations were detected in samples from
infants in the SWEN trial who received nevirapine for the
prevention of mother-to-child transmission of HIV. Overall,
43% (23/53) of the infants had NNRTI mutations detected
(Y181C [n ⫽ 9], Y188C [n ⫽ 5], K103N [n ⫽ 4], G190A [n ⫽
4], and V106M [n ⫽ 1]). Antiretroviral drug resistance mutations were also detected in 7 (17%) of 41 samples from the
P1060 trial (NNRTI mutations: Y181C [n ⫽ 4] and K103N
[n ⫽ 2]; NRTI mutations: M184V [n ⫽ 2], K65R [n ⫽ 1], and
L74V [n ⫽ 1]; one child had K65R, Y181C, and M184V, and
a second child had L74V and Y181C [Fig. 2]).
Comparison between DBS and plasma genotypes. A single
blood collection was used to prepare the DBS and plasma
samples for a subset of infants in the P1060 trial. HIV
genotyping results were obtained for 41 (84%) of the 49
DBS samples analyzed (Table 1); genotyping results from
the ViroSeq HIV-1 genotyping system were obtained previously from plasma samples matched to 34 of those 41 sam-
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ples (Fig. 2) (11). Phylogenetic analysis of HIV sequences
obtained from analysis of DBS and plasma samples grouped
together as expected, confirming the absence of sample mixups (Fig. 2).
Drug resistance mutations were detected in samples from 6
of 34 children who had results obtained for both DBS and
plasma. In all six cases, the same major drug resistance mutations were detected in both samples (Fig. 2). In one sample, an
amino acid substitution at position 215 of HIV reverse transcriptase (T215I) was detected in plasma by using the ViroSeq
HIV genotyping system but was not detected in the DBS sample by using in-house assay #3.

using samples with a variety of drug resistance mutations present at different levels in the viral population. Third, the methods used in this report provide information for HIV reverse
transcriptase only. Methods that include analysis of HIV-1
protease are needed, particularly since the WHO now recommends protease inhibitor-based regimens for infants and
children with prior exposure to nevirapine prophylaxis (14);
NVP-based regimens are widely used for prophylaxis in resource-constrained countries. Analysis of both HIV reverse
transcriptase and protease from DBS samples is likely to require amplification of multiple amplicons because HIV RNA
can become degraded during storage and/or extraction; in contrast, commercially available assays that use plasma for analysis
typically obtain information for both HIV protease and HIV
reverse transcriptase from a single amplicon. Fourth, the methods used in this report rely on nested PCR for DNA amplification; nested PCR can increase the risk of sample crosscontamination and may bias the proportion of viral variants
represented in the amplified DNA product. Finally, we used
three different methods for RT-PCR (different primer sets and
amplification conditions); different numbers of DBS spots
were also used for testing. Therefore, the amounts of blood
used for analysis varied among the samples tested.
Nevertheless, the overall success of obtaining genotypes in
this study and the high concordance with plasma genotypes
coupled with the fact that many laboratories in resource-constrained settings are already familiar with use of DBS samples
for infant diagnostic testing (6) suggest that in-house DBS
genotyping assays provide an alternative for antiretroviral drug
resistance testing in children in resource-constrained regions
but may require region-specific optimization before widespread use.

DISCUSSION
In this study, we evaluated the yield of HIV genotyping of
DBS samples obtained from HIV-infected children enrolled in
clinical trials in sub-Saharan Africa (1, 11). HIV genotypes for
reverse transcriptase were successfully obtained for 94 (90%)
of 105 samples analyzed, despite collection and long-term storage in countries with differing temperature, humidity, and storage conditions. However, it is important to emphasize that
three different primer sets were required to achieve this success rate, with 16.1% (15 of 94 samples) failing to amplify on
the first attempt and requiring a second step of testing (onestep PCR on previously synthesized cDNA with a different
method that produced shorter, overlapping amplicons). While
incorporation of repeat testing with multiple short amplicons
enhanced the recovery of genotypes in the samples tested from
the first clinical trial (tested using assay #1), switching to assay
#3, which included a combination of the outermost primers of
the short, overlapping primers that we previously reported for
pyrosequencing of subtype C HIV reverse transcriptase (10)
and involved testing of samples from five countries (South
Africa, Uganda, Malawi, Zimbabwe, and Tanzania), increased
the yield of genotyping to nearly 90% for samples that were
stored optimally. The addition of the repeat testing increased
the success rate by 3% for optimally stored samples and 13%
for those that were suboptimally stored, highlighting the importance of optimal storage conditions for the genotyping of
DBS. Importantly, with assay #3, a subset of the samples from
the P1060 trial had matched plasma samples that were analyzed previously using an FDA-cleared HIV genotyping kit.
For the pretreatment samples that were analyzed with both
methods in a blind manner, results from DBS genotyping were
100% concordant with plasma genotyping for major drug-resistant mutations obtained using the FDA-cleared genotyping
kit. Together, these findings suggest that the primers used in
assay #3 may be suitable for application in sub-Saharan Africa.
There are several limitations to this study. First, all of the
samples tested were obtained from infants and children who
were not receiving antiretroviral therapy at the time of sample
collection. Therefore, HIV viral loads in the samples were
high, facilitating HIV nucleic acid recovery and amplification
from DBS samples. The proportion of samples successfully
genotyped with DBS may be lower when samples with lower
viral loads (e.g., those obtained at the time of treatment failure) are tested. Second, most of the samples analyzed did not
have drug resistance mutations; further evaluation of the sensitivity for detecting mutations using DBS samples is needed,
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